Myxedema coma, represents the extreme degree of severity of hypothyroidism, whose mortality can reach very high percentages, therefore, it is a true medical emergency. In general, its development is associated with the presence of a triggering factor in a controlled hypothyroid patient and manifests with multisystem alteration. Currently, tools have been developed for clinical diagnosis that use the profile and clinical models, and have good sensitivity-specificity. They allow an early diagnosis which favored the early start of treatment and therefore improves the prognosis. The patient with myxedema coma needs an integral approach, with intensive treatment and close monitoring of hemodynamic parameters. However, the basis of treatment remains hormone replacement, which should be initiated with a combination of levothyroxine and triiodothyronine.
V. Mathew, R.A. Misgar , S. Ghosh, et al. Myxedema coma: a new look in to an old crisis. J Thyroid Res. 2011; 1: 493-462.
J. Hampton. Thyroid gland disorder emergencies: thyroid storm and myxedema coma. AACN. Adv Crit Care. 2013; 24:325–32.
G. Popoveniuc, L. Wartofsky, et al. A diagnostic scoring system for myxedema coma. Endocrine Practice, 2014; 20: 808-817.
Yien V. Chiong. Development of an objective tool for the diagnosis of myxedema coma. Translational Research, 2015, 166(3): 233-245.
J. Nicoloff, J. Lopresti. Myxedema coma, a form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993; 22: 279–90.
L. Wartofsky, Myxedema Coma. Endocrinol Metab Clinic North America. 2006. 35: 687–698.
S. Chakraborty, J. Fedderson, J.J. Gums , Toole A. Amiodarone-induced myxedema coma: a case and review of the literature. Arch Med Sci. 2014; 6: 1263-1268.
N. Stathatos, L. Wartofsky. Perioperative management of patients with hypothyroidism. Endocrinol Metab Clin North Am. 2003; 32:503–518.
N.O. Turhan, M.C. Kockar, I. Inegol. Myxedematous coma in a laboring woman suggested a pre-eclamptic coma: a case report. Acta Obstet Gynecol Scand. 2004; 83:1089–1891.
M. Chu, T.F. Seltzer. Myxedema coma induced by ingestion of raw bok choy, N England J Medicine. 2010. 362(20): 1945–1946.
S. Danzi, I. Klein. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012; 96:257-268.
I. Khochtali, N. Hamza . Reversible dilated cardiomyopathy caused by hypothyroidism. International Archives of Medicine. 2011; 4:20-26.
R.E Watanakunakorn, R.E Hodges. Myxedema: A Story of 400 Cases. Arch Intern Med. 1965; 116:183-190.
J.C. Ravi Shankar, H. Ramesh, N. Hebsur. Hypothyroidism as a Rare Cause for Ogilvie Syndrome. Journal of Dental and Medical Sciences. 2015. 14(4): 32-34.
R.W Skowsky, T.A Kikuchi. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 1978; 64: 613–621.
V. Sanders. Neurologic manifestations of myxedema. New Engl Journal Medicine. 1962; 266:547–551.
T.W Heinrich, G. Grahm. Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited. Prim Care Companion J Clin Psychiatry. 2003; 5:260–266.
I. Espinoza, R. Ramos, A.M Maroon. Myxedema madness. Hipotiroidismo que debuta como psicosis. Rev Psiquiatr Salud Ment. 2010; 3(3): 111–112.
W. Reinhardt, K. Mann. Incidence, clinical picture, and treatment of hypothyroid coma: results of a survey. Med Klin 1997; 92: 521–4.
A. Kogan, K. Yigal. Severe hypothermia in myxedema coma: A rewarming by extracorporeal circulation. Emergency Medicine Australasia. 2011. 23: 773–775.
T. Yamamoto. Delayed respiratory failure during the treatment of myxedema coma. Endocrinol Japan. 1984; 31: 769–775.
T.C. Kamilaris, C.R DeBold, S.N. Pavlou. Effect of altered thyroid hormone levels on hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab. 1987; 65:994-999.
S. Crunkhorn, M.E. Patti. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid. 2008; 18:227-237.
Y. Iwasaki, Y. Oiso, K. Yamauchi. Osmoregulation of plasma vasopressin in myxedema. J Clin Endocrinol Metab. 1990; 70:534-539.
M. Altay, M. Duranay, M. Ceri. Rhabdomyolysis due to hypothyroidism. Nephrol Dialysis Transp.2004. 20(4): 847–848.
Z.Y. Chang, A.Y. Boo. Rhabdomyolysis: A rare complication of hypothyroidism. Proceedings of Singapore Healthcare 2015. 24(3): 188-190.
F. Leonard, I. Rizzo, L. Daniela. Coma mixedematoso. Rev Medicina. 2017; 77: 321-328.
B. Nygaard. Effect of combination therapy with thyroxine (T4) and 3,5,3-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009; 161: 895–902.
E.A. McAninch, A.C. Bianco. New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism. Lancet Diabetes Endocrinol. 2015; 3: 756–758.
J. Garber, R. Cobin, H. Gharib. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18 (6):1004.
J. Jonklaas, C.B. Antonio. Guidelines for the Treatment of Hypothyroidism. Am. Thyroid Assoc. Thyroid. 2014. 24(12): 1670-1752.
T. Yamamoto, J. Fukuyama, A. Fujiyoshi. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 2009. 9: 1167–1174.
P.W. Ladenson, P.D. Goldenheim, D.S. Cooper, M.A. Miller. Early peripheral responses to intravenous L-thyroxine in primary hypothyroidism. Am J Med. 1982. 73:467–474.
K. Boelaert. Prevalence and Relative Risk of Other Autoimmune Diseases in Subjects with Autoimmune Thyroid Disease. American J Med. 2010. 123(12): 1831-9.
J.F. Nickerson, S.R Hill, J.H. McNeil, S.B Barker. Fatal myxedema, with or without coma. Ann Intern Med. 1999. 53;175-193.
R.M. Jordan. Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Medical Clinics of North America. 1995. 79:185–194.
O. Yosuke, O. Sachiko. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. Journal of Epidemiology. 2017. 27: 117-122.
This work is licensed under a Creative Commons Attribution 4.0 International License.